# A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

> **NCT00165672** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 26 (actual)

## Conditions studied

- Non-erosive Gastroesophageal Reflux Disease

## Interventions

- **DRUG:** RABEPRAZOLE SODIUM
- **DRUG:** RABEPRAZOLE SODIUM

## Key facts

- **NCT ID:** NCT00165672
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2011-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165672

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165672, "A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00165672. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*